Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Feb 25

PMID 36835981

Authors

Laeeq Ur Rehman

Muhammad Hassan Nisar

Wajeeha Fatima

Azza Sarfraz

Nishwa Azeem

Zouina Sarfraz

Karla Robles-Velasco

Ivan Cherrez-Ojeda

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the most commonly diagnosed cancer in men worldwide, making up 21% of all cancer cases. With 345,000 deaths per year owing to the disease, there is an urgent need to optimize prostate cancer care. This systematic review collated and synthesized findings of completed Phase III clinical trials administering immunotherapy; a current clinical trial index (2022) of all ongoing Phase I-III clinical trial records was also formulated. A total of four Phase III clinical trials with 3588 participants were included administering DCVAC, ipilimumab, personalized peptide vaccine, and the PROSTVAC vaccine. In this original research article, promising results were seen for ipilimumab intervention, with improved overall survival trends. A total of 68 ongoing trial records pooling in 7923 participants were included, spanning completion until June 2028. Immunotherapy is an emerging option for patients with prostate cancer, with immune checkpoint inhibitors and adjuvant therapies forming a large part of the emerging landscape. With various ongoing trials, the characteristics and premises of the prospective findings will be key in improving outcomes in the future.

Citing Articles

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.

Khorasanchi A, Hong F, Yang Y, Singer E, Wang P, Li M Cancer Drug Resist. 2025; 8:9.

PMID: 40051495 PMC: 11883235. DOI: 10.20517/cdr.2024.173.

The Tight Relationship Between the Tumoral Microenvironment and Radium-223.

Conte M, Tomaciello M, De Feo M, Frantellizzi V, Marampon F, De Cristofaro F Biomedicines. 2025; 13(2).

PMID: 40002869 PMC: 11853176. DOI: 10.3390/biomedicines13020456.

mtPCDI: a machine learning-based prognostic model for prostate cancer recurrence.

Cheng G, Xu J, Wang H, Chen J, Huang L, Qian Z Front Genet. 2024; 15:1430565.

PMID: 39296545 PMC: 11408181. DOI: 10.3389/fgene.2024.1430565.

Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.

Fieni C, Sorrentino C, Ciummo S, Fontana A, Lotti L, Scialis S Exp Mol Med. 2024; 56(9):2033-2051.

PMID: 39232121 PMC: 11447253. DOI: 10.1038/s12276-024-01310-2.

Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.

Rahman M, Akter K, Ahmed K, Maharub Hossain Fahim M, Aktary N, Park M Cancers (Basel). 2024; 16(16).

PMID: 39199550 PMC: 11352813. DOI: 10.3390/cancers16162777.

References

Wang I, Song L, Wang B, Kalebasty A, Uchio E, Zi X . Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022; 10(4):210-233. PMC: 9428569. View

Runcie K, Budman D, John V, Seetharamu N . Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med. 2018; 24(1):50. PMC: 6154901. DOI: 10.1186/s10020-018-0051-4. View

Deluce J, Cardenas L, Lalani A, Maleki Vareki S, Fernandes R . Emerging Biomarker-Guided Therapies in Prostate Cancer. Curr Oncol. 2022; 29(7):5054-5076. PMC: 9319825. DOI: 10.3390/curroncol29070400. View

Vaddepally R, Kharel P, Pandey R, Garje R, Chandra A . Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel). 2020; 12(3). PMC: 7140028. DOI: 10.3390/cancers12030738. View

Lasek W, Zapala L . Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology. Cent European J Urol. 2021; 74(3):300-307. PMC: 8552937. DOI: 10.5173/ceju.2021.0094. View

Luke J, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V . Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022; 399(10336):1718-1729. DOI: 10.1016/S0140-6736(22)00562-1. View

Ishii N, Hatakeyama S, Yoneyama T, Tanaka R, Narita T, Fujita N . Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids. Urol Oncol. 2022; 40(10):451.e1-451.e8. PMC: 9339980. DOI: 10.1016/j.urolonc.2022.07.015. View

Gust J, Taraseviciute A, Turtle C . Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs. 2018; 32(12):1091-1101. PMC: 7295115. DOI: 10.1007/s40263-018-0582-9. View

Jafari S, Molavi O, Kahroba H, Hejazi M, Maleki-Dizaji N, Barghi S . Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell Mol Life Sci. 2020; 77(19):3693-3710. PMC: 11104895. DOI: 10.1007/s00018-020-03459-1. View

10.

Horn L, Spigel D, Vokes E, Holgado E, Ready N, Steins M . Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933. PMC: 6075826. DOI: 10.1200/JCO.2017.74.3062. View

11.

Graff J, Beer T, Alumkal J, Slottke R, Redmond W, Thomas G . A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J Immunother Cancer. 2020; 8(2). PMC: 7333874. DOI: 10.1136/jitc-2020-000642. View

12.

Sater H, Marte J, Donahue R, Walter-Rodriguez B, Heery C, Steinberg S . Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. J Immunother Cancer. 2020; 8(1). PMC: 7174144. DOI: 10.1136/jitc-2020-000655. View

13.

Bilusic M, Gulley J . Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. J Natl Cancer Inst. 2021; 113(7):799-800. PMC: 8246798. DOI: 10.1093/jnci/djaa217. View

14.

Khadka R, Sakemura R, Kenderian S, Johnson A . Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019; 11(10):851-857. DOI: 10.2217/imt-2019-0074. View

15.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

16.

Fizazi K, Drake C, Beer T, Kwon E, Scher H, Gerritsen W . Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. 2020; 78(6):822-830. PMC: 8428575. DOI: 10.1016/j.eururo.2020.07.032. View

17.

Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaitre F . A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021; 6(57). DOI: 10.1126/sciimmunol.abd4344. View

18.

Mughees M, Kaushal J, Sharma G, Wajid S, Batra S, Siddiqui J . Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis. Semin Cancer Biol. 2022; 86(Pt 3):497-512. PMC: 9793433. DOI: 10.1016/j.semcancer.2022.02.017. View

19.

Narayan V, Barber-Rotenberg J, Jung I, Lacey S, Rech A, Davis M . PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022; 28(4):724-734. PMC: 10308799. DOI: 10.1038/s41591-022-01726-1. View

20.

Dang Q, Sun Z, Wang Y, Wang L, Liu Z, Han X . Ferroptosis: a double-edged sword mediating immune tolerance of cancer. Cell Death Dis. 2022; 13(11):925. PMC: 9637147. DOI: 10.1038/s41419-022-05384-6. View